1Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project[J]. J Neurosurg, 2003,99:467-473.
2Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical triMs[J]. Int J Radiat Oncol Biol Phys, 1993,26: 239-244.
3Lacroix M, Abi-Said D, Fourney DRL, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival [J]. Neurosurg, 2001,95(2):190-198.
4Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol[J]. Int J Radiat Oncol Biol Phys, 2004,60(3):853-860.
5Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Onco, 2009,10(5):459-466.
6Khan RB, Raizer JJ, Malkin MG, et al. A phase Ⅱ study of extended low-dose temozolomide in recurrent malignant gliomas[J]. Neuro-oncol, 2002,4:39-43.
7Wick W, Steinbach JP, Kuker WM, et al. One week on/ one week off: a novel active regimen of temozolomide for recurrent glioblastoma[J]. Neurology, 2004,62:2113-215.
8Alarke JL, Iwamoto FM, Sul J, et al. Randomized phase Ⅱ trial of chemoradiotherapy followed by either dose- dense or metronomic temozolomide for newly diagnosed glioblastoma[J]. J Clin Oncol, 2009,7(23):3861-3867.
9Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial [J]. J Clin Oncol, 2001,19(2):509-518.
10Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J]. J Clin Oncol, 2009,7(28):4733-4740.
